Groningen, August 17, 2007 – Oncology focused pharmaceutical company Kiadis Pharma announced today that it has enrolled the last patient in its Phase I/II clinical trial of Rhitol™ that is being conducted in Canada and the United States. The patients enrolled in the clinical trial were randomized to either a low or a high dose to evaluate Rhitol as a treatment option for patients with extensive steroid resistant or intolerant chronic Graft versus Host Disease (GvHD). Rhitol would fulfill a significant unmet medical need for patients with steroid resistant or intolerant chronic GvHD. The disease can develop into a life-threatening condition and there are currently no other standard treatment options available.
